The number of circulating CD26 expressing cells is decreased in critical COVID-19 illness
Cytometry. Part A : the journal of the International Society for Analytical Cytology
We evaluated the number of CD26 expressing cells in peripheral blood of patients with COVID-19 within 72 h of admission and on day 4 and day 7 after enrollment. The majority of CD26 expressing cells were presented by CD3 CD4 lymphocytes. A low number of CD26 expressing cells were found to be associated with critical-severity COVID-19 disease. Conversely, increasing numbers of CD26 expressing T cells over the first week of standard treatment was associated with good outcomes. Clinically, the number of circulating CD26 cells might be a marker of recovery or the therapeutic efficacy of anti-COVID-19 treatment. New therapies aimed at preserving and increasing the level of CD26 expressing T cells may prove useful in the treatment of COVID-19 disease.
deKay JT, May TL, Riker RR, et al. The number of circulating CD26 expressing cells is decreased in critical COVID-19 illness [published online ahead of print, 2022 Mar 4]. Cytometry A. 2022;10.1002/cyto.a.24547. doi:10.1002/cyto.a.24547